After the shocking decision of an advisory committee recommendation that the FDA reject MDMA as a treatment for post-traumatic stress disorder, I wanted to speak to someone who understands the difference between clinical trials and private practice. Dr. Jennifer Tippett is a licensed clinical psychologist and Director of Psychotherapeutic Development at atai Life Sciences, where she creates therapeutic protocols and provides facilitator training for psychedelic clinical trials.

On the show, we start with Jennifer’s experience in forensic psychology. Then we discuss the difference between industry trials, academic trials, and private practice. We talk about making novel psychedelics, and if it is possible, or desired, to make a psychedelic that doesn’t have the trip. We also discussed equity and access, including both cultural and financial barriers to psychedelic healing. Jennifer has spent a lot of time considering how one might create a sustainable business model for psychedelic therapy, especially looking at what has been going on in Oregon. As an employee of atai Life Sciences, which is a publicly traded company, Jennifer responds to some criticisms of for-profit psychedelic companies. And finally, we end with her response to the recent FDA advisory finding against using MDMA for post-traumatic stress disorder.

Jennifer previously directed the Substance Use Disorder Specialty Program at the University of Denver, focusing on addiction and the neurobiology of trauma. Her early career involved working with incarcerated individuals and those with severe mental illness, inspiring her to explore innovative mental health care, including psychedelic medicine. Dr. Tippett studied psychedelics through shamanistic traditions and obtained certifications from Fluence, Polaris, MAPS, and the Integrated Psychiatry Institute. She is also a Level 1 Internal Family Systems provider, dedicated to integrating psychedelics with evidence-based therapies. In her private practice she supports clients with psychedelic integration. 

The views and opinions expressed by Jennifer in this episode are her own and do not necessarily represent those of atai Life Sciences. 
Links
<ul>
 <li><a href="https://www.drjennifertippett.com/">Integration | Jennifer Tippett psychologist</a></li>
 <li><a href="https://atai.life/people/jennifer-tippett/">Jennifer Tippett, Ph.D. atai Life Sciences</a></li>
</ul>
Timestamps
<ul>
 <li>(07:00) - Could psychedelic therapy help treat psychopathy? </li>
 <li>(15:30) - The difference between industry trials, academic trials, and private practice</li>
 <li>(20:30) - Should we make new psychedelics?</li>
 <li>(25:00) - Equity and access, culturally and financially</li>
 <li>(30:30) - Creating sustainable business models for psychedelics therapists</li>
 <li>(35:30) - Could we have healing without the trip?</li>
 <li>(39:30) - Responding to criticism of for profit psychedelic companies</li>
 <li>(42:30) - Responding to FDA advisory board’s decision on MDMA</li>
</ul>

Podurama

Home

Trending

Personal

Your Podcasts

New Episodes

My Files

Favourite Episodes

Tags (Folders)

Recently Played

Bookmarks

Followed Playlists

Jennifer Tippett: Understanding Private Practice vs Clinical Trials

The Psychedelic Therapy Podcast

AI Chapters

AI Insights

Reviews